Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $32.29

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $32.29.

Several research firms have issued reports on DAWN. Needham & Company LLC restated a "buy" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Wedbush restated an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock traded up $0.07 on Friday, hitting $7.75. The stock had a trading volume of 485,719 shares, compared to its average volume of 1,057,438. The firm has a market capitalization of $785.49 million, a P/E ratio of -7.52 and a beta of -1.24. The stock has a 50 day moving average of $8.18 and a 200 day moving average of $11.50. Day One Biopharmaceuticals has a twelve month low of $6.41 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million. Equities analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. The trade was a 8.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares of the company's stock, valued at $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock worth $251,925 in the last quarter. 6.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC grew its stake in Day One Biopharmaceuticals by 7.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company's stock valued at $346,000 after buying an additional 1,805 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 5.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company's stock worth $454,000 after acquiring an additional 1,894 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $27,000. China Universal Asset Management Co. Ltd. lifted its holdings in Day One Biopharmaceuticals by 11.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company's stock worth $271,000 after purchasing an additional 2,180 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Day One Biopharmaceuticals by 19.6% during the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after purchasing an additional 2,407 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.